Patents by Inventor Dagmar Schlenzig
Dagmar Schlenzig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230122243Abstract: The present invention relates to novel hydroxamic acid derivatives useful as inhibitors of astacin metalloproteinases, in particular procollagen C-proteinase (PCP) enzymes, meprins, ovastacin and/or nematode astacins; more particularly human or mammalian meprin ?, meprin ?, BMP-1, ovastacin and/or DPY-31 from nematodes; pharmaceutical compositions comprising such compounds; methods for treatment or prophylaxis of diseases or conditions, especially such that are related to said metalloproteinases; and compounds and pharmaceutical compositions for use in such methods.Type: ApplicationFiled: June 12, 2020Publication date: April 20, 2023Inventors: Daniel RAMSBECK, Kathrin TAN, Dagmar SCHLENZIG, Mirko BUCHHOLZ, Holger CYNIS, Stephan SCHILLING
-
Publication number: 20210198189Abstract: The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin ? and/or ?, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin ? and/or ?, and compounds and pharmaceutical compositions for use in such methods.Type: ApplicationFiled: March 8, 2021Publication date: July 1, 2021Applicant: Vivoryon Therapeutics AGInventors: Michael Wermann, Mirko Buchholz, Hans-Ulrich Demuth, Daniel Ramsbeck, Dagmar Schlenzig, Stephen Schilling
-
Patent number: 10975019Abstract: The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin ? and/or ?, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin ? and/or ?, and compounds and pharmaceutical compositions for use in such methods.Type: GrantFiled: April 18, 2017Date of Patent: April 13, 2021Assignee: Vivoryon Therapeutics AGInventors: Michael Wermann, Mirko Buchholz, Hans-Ulrich Demuth, Daniel Ramsbeck, Dagmar Schlenzig, Stephen Schilling
-
Publication number: 20190127317Abstract: The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin ? and/or ?, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin ? and/or ?, and compounds and pharmaceutical compositions for use in such methods.Type: ApplicationFiled: April 18, 2017Publication date: May 2, 2019Inventors: Michael Wermann, Mirko Buchholz, Hans-Ulrich Demuth, Daniel Ramsbeck, Dagmar Schlenzig, Stephen Schilling
-
Publication number: 20110152341Abstract: Methods and means for the identification of meprin-? and meprin-? as novel ?-secretases and antagonists thereof for use in the treatment of amyloidosis.Type: ApplicationFiled: December 22, 2010Publication date: June 23, 2011Applicant: PROBIODRUG AGInventors: Stephan Schilling, Dagmar Schlenzig, Hans-Ulrich Demuth
-
Publication number: 20080182798Abstract: Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in mammals.Type: ApplicationFiled: May 30, 2006Publication date: July 31, 2008Inventors: Hans-Ulrich Demuth, Konrad Glund, Dagmar Schlenzig, Susanne Kruber
-
Patent number: 7335645Abstract: The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain; B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g/mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine.Type: GrantFiled: March 1, 2005Date of Patent: February 26, 2008Assignee: Probiodrug AGInventors: Hans-Ulrich Demuth, Torsten Hoffmann, Dagmar Schlenzig, Ulrich Heiser
-
Patent number: 7166579Abstract: Prodrug compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The Prodrug compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy.Type: GrantFiled: December 11, 2003Date of Patent: January 23, 2007Assignee: Prosidion LimitedInventors: Hans-Ulrich Demuth, Dagmar Schlenzig, Torsten Hoffmann, Susanne Manhart
-
Patent number: 7084120Abstract: Prodrug compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The Prodrug compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy.Type: GrantFiled: December 22, 2000Date of Patent: August 1, 2006Assignee: Probiodrug AGInventors: Hans-Ulrich Demuth, Dagmar Schlenzig, Torsten Hoffmann, Susanne Manhart
-
Patent number: 6949515Abstract: The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain; B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g/mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine.Type: GrantFiled: February 22, 2002Date of Patent: September 27, 2005Assignee: Probiodrug AGInventors: Hans-Ulrich Demuth, Torsten Hoffmann, Dagmar Schlenzig, Ulrich Heiser
-
Publication number: 20050209159Abstract: The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain; B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g/mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine.Type: ApplicationFiled: March 1, 2005Publication date: September 22, 2005Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Dagmar Schlenzig, Ulrich Heiser
-
Publication number: 20050203030Abstract: Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in mammals.Type: ApplicationFiled: December 2, 2003Publication date: September 15, 2005Inventors: Hans-Ulrich Demuth, Konrad Glund, Dagmar Schlenzig, Susanne Kruber
-
Publication number: 20040171555Abstract: The present invention relates to prodrug compounds of inhibitors of dipeptidyl peptidase IV (DP IV), which prodrug compounds have the general formula A-B-C, whereinType: ApplicationFiled: December 11, 2003Publication date: September 2, 2004Inventors: Hans-Ulrich Demuth, Dagmar Schlenzig, Torsten Hoffmann, Susanne Manhart
-
Publication number: 20030134802Abstract: Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in mammals.Type: ApplicationFiled: February 10, 2003Publication date: July 17, 2003Inventors: Hans-Ulrich Demuth, Konrad Glund, Dagmar Schlenzig, Susanne Kruber
-
Publication number: 20030092630Abstract: The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula 1 wherein A is an amino acid having at least one functional group in the side chain;B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g/mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine.Type: ApplicationFiled: February 22, 2002Publication date: May 15, 2003Applicant: probiodrug AGInventors: Hans-Ulrich Demuth , Torsten Hoffmann , Dagmar Schlenzig , Ulrich Heiser
-
Patent number: 6548481Abstract: Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in mammals.Type: GrantFiled: November 28, 2000Date of Patent: April 15, 2003Assignee: Probiodrug AGInventors: Hans-Ulrich Demuth, Konrad Glund, Dagmar Schlenzig, Susanne Kruber
-
Publication number: 20020165164Abstract: The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula 1Type: ApplicationFiled: February 22, 2002Publication date: November 7, 2002Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Dagmar Schlenzig, Ulrich Heiser
-
Publication number: 20020049164Abstract: The present invention relates to prodrug compounds of inhibitors of dipeptidyl peptidase IV (DP IV), which prodrug compounds have the general formula A-B-C, whereinType: ApplicationFiled: December 22, 2000Publication date: April 25, 2002Inventors: Hans-Ulrich Demuth, Dagmar Schlenzig, Torsten Hoffmann, Susanne Manhart